It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.
Barry Clare, Non-Executive Chairman
Barry has over 20 years’ experience in the healthcare industry. He was a former main board director of the Boots Company plc and Chairman of University Hospital South Manchester (UHSM) Foundation Trust. As the former Managing Director of Boots Healthcare International, he led the global expansion of a leading portfolio of brands including Nurofen, Strepsils and Clearasil. Since leaving Boots, he has set up his own company, Clarat Partners LLP, and engineered several private equity backed transactions.
Dr Stephen Franklin, Chief Executive Officer
Stephen founded Evgen Pharma in 2007 and has over 20 years’ experience in the life science industries, focusing on the commercialisation of new technology. He was formally the CEO of Provexis plc (a spin-out from ANGLE plc), leading it from seed investment through to, and beyond, its admission to AIM in 2005. Stephen has a BSc in Biology (York), a PhD in Applied Biochemistry (Nottingham) and an MBA with distinction (Nottingham). He is a Fellow of the Royal Society of Medicine and an alumni of the Royal Commission for the Exhibition of 1851.
Richard Moulson, Chief Financial Officer
Richard is a qualified chartered accountant with over 20 years’ post-qualification experience working as a chief financial officer for UK quoted and private equity and venture capital owned companies. Richard trained with Coopers & Lybrand and spent 10 years with Deutsche Morgan Grenfell in corporate finance working on fundraisings, IPOs and M&A transactions in the UK and internationally. He has considerable life science experience in companies including Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics.
Dr Alan Barge, Non-Executive Director
Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.
Dr Susan Foden, Non-Executive Director
Susan has broad experience in executive and non-executive roles at both public and private companies and at funding organisations. Her current directorships include Vectura plc and BTG plc and she was the former Chair at BerGenBio AS. She is a former investor director with Merlin Biosciences and, from 1987 to 2000, was chief executive officer of the technology transfer company Cancer Research Campaign Technology Limited. She studied biochemistry at the University of Oxford, obtaining an MA and a DPhil.
Dr Marc d’Abbadie, Non-Executive Director
Marc is an investor director at SPARK Impact, managers of the North West Fund for Biomedical. He was previously at Inventages, which manages one of the world’s largest life-science focused venture capital funds with assets of $1.5bn, and Technikos, a medical device venture capital investor. Prior to being a consultant at McKinsey & Co., Marc was a research fellow at Trinity College Cambridge. He obtained his MA in Natural Sciences from Trinity College Cambridge and his PhD in Biochemistry from the MRC Laboratory of Molecular Biology, also at Cambridge.
Sally Ross, Clinical Development Officer
Sally has over 18 years of experience working across pre-clinical and clinical settings in academia, pharma and CROs. Sally held many different roles at AstraZeneca, starting off as a translational Scientist working on Iressa and then moved into more clinical roles as a Global Project/Programme Manager in the Oncology and Infection Therapeutic Areas, and subsequently as a Principal Medical Scientist in both early and late clinical development. Upon leaving AstraZeneca Sally worked for a large mid-sized contract research organisation as Director of Project Management.
Dr Thomas Morris – Medical Advisor
Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies.
Liz Jenkins – Regulatory Consultant
Liz Jenkins is a specialist in International Regulatory Affairs with over 30 years’ experience in the biopharmaceutical sector. She started her career at the East Birmingham and Royal Free Hospitals before joining Celltech Ltd (now UCB Celltech) in 1983 and the Amgen in 1993. Since 1998 Liz has operated as both an independent or affiliated consultant offering strategic advice and practical assistance in the areas of drug development, clinical trials, regulatory affairs and product licensing to more than 50 different biopharmaceutical companies.